Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.» Read More
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
The delay of Obamacare's employer mandate isn't a blow to health-care stocks. However, the outlook for reform is another matter.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.
Some of the names on the move ahead of the open.
Cramer has become more cautious on the market right now and conditions are creating a "nightmare scenario" for just about everyone involved, he said on CNBC.
“I’m not crazy about the market,” Cramer said. Now what?
“The price action is confounding more people than I have seen in some time,” said Cramer. What's going on?
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Take a look at some of Monday's midday movers:
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Several key areas are dangerous for investors in this economic environment, said Jim Cramer, and his charitable trust sold two key stocks.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
Stocks closed down 1 percent after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Take a look at some of Wednesday midday movers:
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
A pullback would be healthy for the stock market — and may be overdue, Josh Brown says.
U.S. stock index futures were higher Thursday, lifted by a batch of better-than-expected earnings and after an upbeat jobless claims report.
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?